References
1. Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. Int J Cardiol. 2016; 203: 279–81. https://doi.org/10.1016/j.ijcard.2015.10.172
2. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, et al. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138(7):678-91. https://doi.org/10.1161/CIRCULATIONAHA.117.030816
3. Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities. Herz. 2020; 45(7): 619–25. https://doi.org/10.1007/s00059-020-04951-x
4. Abdel-Rahman O. Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. Expert Rev Anticancer Ther. 2017;17(9): 873–78. https://doi.org/10.1080/14737140.2017.1344099
5. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015; 65(25): 2739–46. https://doi.org/10.1016/j.jacc.2015.04.059
6. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 2019; 40(22): 1756–63. https://doi.org/10.1093/eurheartj/ehy453
7. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022; 28(5): e1–e167. https://doi.org/10.1016/j.cardfail.2022.02.010
8. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006; 24(25): 4107–15. https://doi.org/10.1200/JCO.2005.04.9551
9. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012; 104(17): 1293–305. https://doi.org/10.1093/jnci/djs317
10. Yoodee J, Sookprasert A, Sanguanboonyaphong P, Chanthawong S, Seateaw M, Subongkot S. An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study. Clin Pract. 2021; 11(3): 484–93. https://doi.org/10.3390/clinpract11030064
11. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3): 213–20. https://doi.org/10.1016/j.jacc.2009.03.095
12. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008; 31(6): 459–67. https://doi.org/10.2165/00002018-200831060-00002
13. Chang WT, Chen PW, Lin HW, Lin SH, Li YH. Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan. ESC Heart Fail. 2021; 8(6): 5149–58. https://doi.org/10.1002/ehf2.13591
14. Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD, et al. Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A SystematicReview and Meta-analysis. CJC Open. 2021; 3(11): 1372–82. https://doi.org/10.1016/j.cjco.2021.06.019
15. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16): 1755–64. https://doi.org/10.1016/j.jacc.2018.02.037
16. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22): 1981–88. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
17. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015; 17(1): 81–9. https://doi.org/10.1002/ejhf.196
18. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013; 61(23): 2355–62. https://doi.org/10.1016/j.jacc.2013.02.072
19. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23): 2474–81. https://doi.org/10.1161/CIRCULATIONAHA.106.635144
20. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019; 73(22): 2859–68. https://doi.org/10.1016/j.jacc.2019.03.495
21. Brown LJ, Meredith T, Yu J, Patel A, Neal B, Arnott C, et al. Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers (Basel). 2021; 13(21): 5527. https://doi.org/10.3390/cancers13215527
22. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018; 71(20): 2281–90. https://doi.org/10.1016/j.jacc.2018.02.049
23. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018; 94: 126–37. https://doi.org/10.1016/j.ejca.2018.02.005
24. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017; 35(8): 870–7. https://doi.org/10.1200/JCO.2016.68.7830
25. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020; 8(10): 800–10. https://doi.org/10.1016/j.jchf.2020.06.020
26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004. https://doi.org/10.1056/NEJMoa1409077
27. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019; 380(6): 539–48. https://doi.org/10.1056/NEJMoa1812851
28. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202–7. https://doi.org/10.1001/jamacardio.2019.4665
29. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997; 336(19): 1350–5. https://doi.org/10.1056/NEJM199705083361903
30. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. Circulation. 1997; 87 (6 Suppl):VI65-70.
31. Correale M, Mallardi A, Tricarico L, Mazzeo P, Ferraretti A, Diella C, et al. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. Acta Cardiol. 2021; 77(5): 416–21. https://doi.org/10.1080/00015385.2021.1950371
32. Duraes AR, de Souza Lima Bitar Y, Neto MG, Mesquita ET, Chan JS, Tse G, et al. Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction (CTRCD): a systematic review of clinical and preclinical studies. Minerva Med. 2022; 113(3): 551–7. https://doi.org/10.23736/S0026-4806.22.08029-6
33. Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017; 108:138-48. https://doi.org/10.1016/j.yjmcc.2017.06.003
34. Dindaş F, Güngör H, Ekici M, Akokay P, Erhan F, Doğduş M, et al. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway. Anatol J Cardiol. 2021; 25(11): 821–8. https://doi.org/10.5152/AnatolJCardiol.2021.356
35. Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, et al. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC CardioOncol. 2020; 2(5): 774–87. https://doi.org/10.1016/j.jaccao.2020.09.007
36. Kim BS, Park IH, Lee AH, Kim HJ, Lim YH, Shin JH. Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2022; 96(4): 1065–74. https://doi.org/10.1007/s00204-022-03241-1
37. Sheppard CE, Anwar M. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series. J Oncol Pharm Pract. 2019; 25(5): 1231–4. https://doi.org/10.1177/1078155218783238
38. Canale ML, Coviello K, Solarino G, Del Meglio J, Simonetti F, Venturini E, et al. Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology. Front Cardiovasc Med. 2022; 9:801143. https://doi.org/10.3389/fcvm.2022.801143
39. Frey MK, Arfsten H, Pavo N, Han E, Kastl S, Hülsmann M, et al. Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data. Cardiooncology. 2021; 7(1): 35. https://doi.org/10.1186/s40959-021-00121-y
40. Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020; 7(2), 763–7. https://doi.org/10.1002/ehf2.12627
41. De Vecchis R, Paccone A. A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. SAGE Open Med Case Rep. 2020; 8:2050313X20952189. https://doi.org/10.1177/2050313X20952189
42. Martín-García A, Díaz-Peláez E, Martín-García AC, Sánchez-González J, Ibáñez B, Sánchez PL. Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2020; 73(3): 268–269. https://doi.org/10.1016/j.rec.2019.07.006
43. Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020; 6(1): 24. https://doi.org/10.1186/s40959-020-00078-4
44. Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021; 188(1):21-36. https://doi.org/10.1007/s10549-021-06280-x
45. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019; 175(3): 595–603. https://doi.org/10.1007/s10549-019-05191-2
46. Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer. Am J Clin Oncol. 2018; 41(9):909–18. https://doi.org/10.1097/COC.0000000000000389
47. Xi Q, Chen Z, Li T, Wang L. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction. J Int Med Res. 2022; 50(1):3000605211067909. https://doi.org/10.1177/03000605211067909
48. Lupi A, Ariotti S, De Pace D, Ferrari I, Bertuol S, Monti L, et al. Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report. Clin Med Insights Cardiol. 2021; 15:11795468211010706. https://doi.org/10.1177/11795468211010706
49. Wu SJ, Liu XH, Wu W, Qian M, Li L, Zhang L, et al. [Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022; 50(4):397-400. Chinese. https://doi.org/10.3760/cma.j.cn112148-20210511-00412
50. Mecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology. 2021; 7(1): 33. https://doi.org/10.1186/s40959-021-00115-w